Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang… - The lancet …, 2014 - thelancet.com
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
被引用次数：2359 相关文章

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang… - The Lancet …, 2014 - europepmc.org
Background Afatinib-an oral irreversible ErbB family blocker-improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li… - The Lancet …, 2014 - infona.pl
Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival
compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …

[引用][C] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang… - The Lancet …, 2014 - cir.nii.ac.jp
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label …
[PDF] vademecum.es

[PDF][PDF] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang… - Lancet …, 2014 - static.vademecum.es
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Afatinib-an oral irreversible ErbB family blocker-improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
[PDF] medric.or.kr

[PDF][PDF] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFRmutations (LUX …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li… - Lancet Oncol, 2014 - medric.or.kr
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li… - The Lancet …, 2014 - Elsevier
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFRmutations (LUX-Lung 6) …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li… - Lancet Oncol, 2014 - thelancet.com
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
[PDF] svadcf.es

[PDF][PDF] Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX …

YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li… - Lancet Oncol, 2014 - svadcf.es
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …